Clinical trials: Metastasis to Liver
Hepatocellular Carcinoma, Liver Metastases
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma…
- Conditions
- Hepatocellular Carcinoma, Liver Metastases, Cholangiocarcinoma
- Trial name
- NCT04676633
- Testing
- STP705
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sirnaomics
Pancreatic Cancer, Hepatocellular Cancer
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
This study is about TAK-500, given either alone or with pembrolizumab, in adults with select locally advanced or metastatic solid tumors.
- Conditions
- Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer
- Trial name
- NCT05070247
- Testing
- TAK-500, Pembrolizumab, Tocilizumab
- Where
- 12 sites in United States
- Volunteers
- 61 people
- Sponsor
- Takeda
Advanced Cancers
HAI Abraxane With Gemcitabine and Bevacizumab
The goal of this clinical research study is to find the highest tolerable dose of Abraxane® (nab-paclitaxel) when given directly into the liver, in combination with Gemzar® (gemcitabine) and Avastin® (bevacizumab) when given by…
- Trial name
- NCT01057264
- Testing
- HAI Abraxane, Gemcitabine, Bevacizumab
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Combined Resection of Colorectal Metastases
This is a Phase II study of combined surgical resection for patients with both intra- and extra-hepatic metastases from colorectal cancer.
- Trial name
- CRC (NCT00606398)
- Testing
- surgical resection for patients with both intra- and extra-hepatic metastases
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
Short-term Effects of LASI Surgery Versus Conventional Laparotomy for Colorectal Liver Metastasis
Surgical resection is still recommended as the optional treatment for colorectal liver metastasis (CLM) patients. There are two main concerns for resectable colorectal liver metastasis which remain controversial: surgical time…
- Trial name
- NCT02350166
- Testing
- laparoscopic surgery
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- West China Hospital
Neuroendocrine Tumors
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
The purpose of this study is to see the safety and activity of using pasireotide, everolimus and radioembolization (Selective Internal Radioembolization Therapy-SIRT) in the treatment of neuroendocrine tumors (carcinoid) that has…
- Trial name
- NCT01469572
- Testing
- Pasireotide, Sir-sphere Radioembolization, Everolimus
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Emory University
Uveal Melanoma, Metastatic Uveal Melanoma
Adding IL-2 to Tebentafusp to Eradicate Cancer Progression
A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group.
- Conditions
- Uveal Melanoma, Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the Liver
- Trial name
- SILVER (NCT07063875)
- Testing
- Aldesleukin
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- St Vincent's Hospital, Sydney
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Liver Metastasis, Gastric Cancer
Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis
Objectives: The purpose of this study is to evaluate the safety and efficacy of PIK-HER2 cells in the treatment of advanced Her2 high expressed gastric cancer with liver metastasis patients.
- Trial name
- NCT02632201
- Testing
- PIK-HER2, DC-PMAT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Military Medical University
Gastric Neoplasms, Esophageal Cancer
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer.
- Conditions
- Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis
- Trial name
- RIOT3 (NCT07001592)
- Testing
- vvDD-hIL-2-RG-1
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Metastatic Colorectal Cancer
Pattern of Cell Death Following Neoadjuvant Therapy for Metastatic Colon Cancer
Systemic chemotherapy for metastatic colon cancer is often used in the neoadjuvant setting for patients undergoing liver resection.
- Trial name
- NCT00414492
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Liver Cancer
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Patients with primary and secondary liver cancer may participate in this study. The purpose is to perform an analysis of the effects of doxorubicin and its metabolite doxorubicinol on the body (doxorubicin pharmacokinetics )…
- Trial name
- NCT02753881
- Testing
- whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Uveal Melanoma, Metastatic Cutaneous Melanoma
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver…
- Trial name
- HAITILS-PHP (NCT05903937)
- Testing
- Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2
- Volunteers
- 6 people
- Sponsor
- Vastra Gotaland Region
Hepatocellular Carcinoma Non-resectable
Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
It is a a single arm, observational clinical trial to evaluate the efficacy and safety of combination treatment with sintilimab injection plus endostar in untreated locally advanced or metastatic hepatocellular carcinoma.
- Trial name
- NCT03881501
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Huazhong University of Science and Technology
Liver Neoplasms, Liver Metastasis
The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver
The CUSA (cavitron ultrasound surgical aspirator) is the method of choice for hepatic resection in our center. Recently a stapler-hepatectomy methods has been developed and approved for liver surgery using Covidien Endo-Gia…
- Conditions
- Liver Neoplasms, Liver Metastasis, Liver Hemangioma, Echinococcosis, Hepatic
- Trial name
- NCT01785212
- Testing
- Stapler, CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Vienna
Neuroendocrine Tumors, Liver Metastases
Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases
The objective is to investigate the impact of intra-arterial administration of 177Lu-dotatate on the intrahepatic biodistribution in patients with NET liver metastases.
- Trial name
- LUTIA (NCT03590119)
- Testing
- Lutetium Lu 177-DOTATATE
- Where
- 3 sites in Netherlands
- Volunteers
- 26 people
- Sponsor
- Marnix Lam
Metastatic Colorectal Cancer, Liver Metastases
FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic colorectal cancer liver metastases.
- Trial name
- NCT03678428
- Testing
- Irinotecan, Oxaliplatin HAI, Floxuridine
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
This pilot clinical trial studies radioembolization and ipilimumab in treating patients with uveal melanoma with liver metastases.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma
- Trial name
- NCT01730157
- Testing
- ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Carcinoma, Colorectal Cancer
Tumor Antigen-sensitized DC Vaccine for Colorectal Cancer Liver Metastases
The aim of this study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of R0 excision Colorectal Cancer Liver Metastases.
- Trial name
- NCT06545630
- Testing
- Tumor antigen-sensitized DC vaccine
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
CRC (Colorectal Cancer), Melanoma (Skin Cancer)
A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors
This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with…
- Conditions
- CRC (Colorectal Cancer), Melanoma (Skin Cancer), HCC - Hepatocellular Carcinoma, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- TGI5 (NCT07376707)
- Testing
- TGI-5
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Hefei TG ImmunoPharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.